TG Therapeutics will host a conference call on August 4, 2025, to discuss Q2 results and future outlook.
Quiver AI Summary
TG Therapeutics, Inc. announced a conference call scheduled for August 4, 2025, at 8:30 AM ET to discuss its second quarter financial results and business outlook for the remainder of 2025, hosted by Chairman and CEO Michael S. Weiss. Participants can join the call via a specified phone number, and a live webcast will also be available on the company's website. An audio recording of the call will be accessible for 30 days afterwards. The company will issue a press release detailing its financial results before the call. TG Therapeutics is focused on developing and commercializing treatments for B-cell diseases, including their FDA-approved medication BRIUMVI® for multiple sclerosis.
Potential Positives
- TG Therapeutics will discuss its second-quarter financial results and business outlook, indicating transparency and engagement with investors.
- The company has received FDA approval for BRIUMVI® for treating multiple sclerosis, highlighting its successful product development and regulatory compliance.
- BRIUMVI® has also been approved by the European Commission and the UK’s MHRA, expanding its market potential and international presence.
Potential Negatives
- None
FAQ
When is the TG Therapeutics earnings call?
The TG Therapeutics earnings call is scheduled for Monday, August 4, 2025, at 8:30 AM ET.
How can I participate in the conference call?
To participate, call 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.).
Where can I listen to the live webcast?
The live webcast will be available on the Events page in the Investors & Media section of TG Therapeutics' website.
Will there be a replay of the conference call?
Yes, an audio recording will be available for replay on the website for 30 days after the call.
What recent approvals has TG Therapeutics received?
TG Therapeutics received FDA approval for BRIUMVI® for multiple sclerosis and approvals from the EC and MHRA in Europe and the UK.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TGTX Insider Trading Activity
$TGTX insiders have traded $TGTX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TGTX stock by insiders over the last 6 months:
- YANN ECHELARD sold 10,000 shares for an estimated $369,400
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TGTX Hedge Fund Activity
We have seen 183 institutional investors add shares of $TGTX stock to their portfolio, and 161 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP removed 1,766,009 shares (-19.2%) from their portfolio in Q1 2025, for an estimated $69,633,734
- OPALEYE MANAGEMENT INC. removed 1,725,000 shares (-76.3%) from their portfolio in Q1 2025, for an estimated $68,016,750
- WELLINGTON MANAGEMENT GROUP LLP added 1,149,526 shares (+1809.9%) to their portfolio in Q1 2025, for an estimated $45,325,810
- CLEARBRIDGE INVESTMENTS, LLC added 809,330 shares (+44.1%) to their portfolio in Q1 2025, for an estimated $31,911,881
- DRIEHAUS CAPITAL MANAGEMENT LLC added 774,656 shares (+inf%) to their portfolio in Q1 2025, for an estimated $30,544,686
- FMR LLC added 711,935 shares (+69.0%) to their portfolio in Q1 2025, for an estimated $28,071,597
- WOODLINE PARTNERS LP added 533,134 shares (+inf%) to their portfolio in Q1 2025, for an estimated $21,021,473
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TGTX Analyst Ratings
Wall Street analysts have issued reports on $TGTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 03/04/2025
To track analyst ratings and price targets for $TGTX, check out Quiver Quantitative's $TGTX forecast page.
Full Release
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the second quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com . An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com , for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features, in Europe and the United Kingdom, respectively. For more information, visit
www.tgtherapeutics.com,
and follow us on X (formerly Twitter)
@TGTherapeutics
and on
LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc. BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor
Relations
Email:
[email protected]
Telephone: 1.877.575.TGTX (8489), Option 4
Media
Relations:
Email:
[email protected]
Telephone: 1.877.575.TGTX (8489), Option 6
